Eisai to Launch New Medikidz Epilepsy Comic Book at the National Walk for Epilepsy

WOODCLIFF LAKE, N.J., March 23, 2017 /PRNewswire/ -- Eisai Inc. is pleased to announce that it will be launching the latest "Medikidz Explain Epilepsy," book as part of their participation at the Epilepsy Foundation's National Walk for Epilepsy on Saturday, March 25th, 2017. The book is the sixth in the series of educational comics designed to inform people about epilepsy and will focus on the transition from pediatric to adult health care.   

The Medikidz superheroes and the comic book's stars

Meet and greet with the Medikidz superheroes and the comic book's stars at the Eisai booth. The Eisai booth will also feature an interactive craft station for kids to design their own superhero capes and attendees will be able to pick up free copies of the book to learn more about epilepsy. The stars of "Understanding Transitional Care in Epilepsy" will be available for on-site interviews and photo opportunities.

Saturday, March 25th, 2017

Washington Monument Grounds, 15th St. and Independence Ave., NW, Washington, DC 20007

The National Walk for Epilepsy, held annually by the Epilepsy Foundation, is a community event for friends, families, corporations and organizations gathering to celebrate their fundraising success and demonstrate their support in the fight against epilepsy. Eisai is attending and sponsoring the event for the 8th year and will be accompanied by friends of the community, Magnolia Paws for Compassion and Jumo Health, creators of the Medikidz series. Money raised from the National Walk for Epilepsy helps the Epilepsy Foundation provide services for people living with epilepsy, bring awareness programs to the community and aid research funding for the condition.

"Medikidz Explain Epilepsy" Comic Book Series  
The "Medikidz Explain Epilepsy" series was first launched in December 2013 in order to help increase education about epilepsy. Eisai co-developed and supported the publication of five previous comic books in the series as further resources for families who are affected by epilepsy. The series is peer-reviewed by leading medical professionals.

About Eisai Inc.  
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.

Media Inquiries:  
Laurie Landau  
Eisai Inc. 


SOURCE Eisai Inc.

Type Press Release

Date Released March 23, 2017

May 9, 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today...

Apr 26, 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced an article about long-term health outcomes of its investigational anti-amyloid-beta (Aβ) protofibril antibody...

Apr 7, 2022

Eisai stands with people living with Alzheimer’s disease (AD), health care professionals and other members of our AD community. We respect that the Centers for Medicare and Medicaid Services...

Alerts - Release page
* Required Fields